Dr. Kubassova and IAG’s Bio-Partnering are Attending Bio, June 3-6, 2019

Slider with alias news slider not found.

Dr. Kubassova and IAG’s Bio-Partnering are Attending Bio International, June 3-6, 2019 in Philadelphia USA.

Dr. Olga Kubassova, CEO of IAG and Venture Partner at Analytics Ventures and Bio Capital Impact Fund will be attending Bio, Philadelphia, USA together with bio-partnering team of IAG. Dr. Kubassova will also be a part of the investment panel to discuss challenges and opportunities for the lifescience industry in the US and China, topics around industry trends and cross-border opportunities between US and China. Given the increasing need for collaboration in therapy development, Dr. Kubassova will introduce IAG’s technology-enabled, risk-sharing and mitigation partnerships, and targeted development strategies.

IAG’s Bio-Partnering team is an independent investment division of IAG that is building a diversified investment portfolio of innovative life science companies at various stages of clinical development, with first partnerships including immuno-oncology, neuro-oncology and immunology focused partners. At the Bio meeting, IAG team seeks to engage with companies and discuss the development of clinical stage assets, IP acquisition from the academic partners and biotech companies, investment partnerships and strategic collaborations.

To find out more about IAG’s Bio-Partnering services or to schedule a meeting during BIO 2019 please send an email to contact@ia-grp.com

About BIO 2019

The BIO International Convention is hosted by the Biotechnology Innovation Organization (BIO), which represents more than 1,100 biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations.  The conference brings together businesses, investors and academics and runs over 500 education sessions and netwrokign events, click here.

About Image Analysis Group (IAG)

IAG, Image Analysis Group is a unique partner to life sciences companies. IAG leverages expertise in medical imaging and the power of Dynamika™ – our proprietary cloud-based platform, to de-risk clinical development and deliver lifesaving therapies into the hands of patients much sooner.  IAG provides early drug efficacy assessments, smart patient recruitment and predictive analysis of advanced treatment manifestations, thus lowering investment risk and accelerating study outcomes. IAG bio-partnering takes a broader view on asset development bringing R&D solutions, operational breadth, radiological expertise via risk-sharing financing and partnering models.

Learn more:  wp1.ia-grp.com

Reach out: imaging.experts@ia-grp.com

Follow the Company: Linkedin